Literature DB >> 34798068

Diagnosis and treatment of primary aldosteronism.

Martin Reincke1, Irina Bancos2, Paolo Mulatero3, Ute I Scholl4, Michael Stowasser5, Tracy Ann Williams6.   

Abstract

Primary aldosteronism is a common cause of secondary hypertension associated with excess cardiovascular morbidities. Primary aldosteronism is underdiagnosed because it does not have a specific, easily identifiable feature and clinicians can be poorly aware of the disease. The diagnostic investigation is a multistep process of screening, confirmatory testing, and subtype differentiation of unilateral from bilateral forms for therapeutic management. Adrenal venous sampling is key for reliable subtype identification, but can be bypassed in patients with specific characteristics. For unilateral disease, surgery offers the possibility of cure, with total laparoscopic unilateral adrenalectomy being the treatment of choice. Bilateral forms are treated mainly with mineralocorticoid receptor antagonists. The goals of treatment are to normalise both blood pressure and excessive aldosterone production, and the primary aims are to reduce associated comorbidities, improve quality of life, and reduce mortality. Prompt diagnosis of primary aldosteronism and the use of targeted treatment strategies mitigate aldosterone-specific target organ damage and with appropriate patient management outcomes can be excellent. Advances in molecular histopathology challenge the traditional concept of primary aldosteronism as a binary disease, caused by either a unilateral aldosterone-producing adenoma or bilateral adrenal hyperplasia. Somatic mutations drive autonomous aldosterone production in most adenomas. Many of these same mutations have been identified in nodular lesions adjacent to an aldosterone-producing adenoma and in patients with bilateral disease. In addition, germline mutations cause rare familial forms of aldosteronism (familial hyperaldosteronism types 1-4). Genetic testing for inherited forms in suspected cases of familial hyperaldosteronism avoids the burdensome diagnostic investigation in positive patients. In this Review, we discuss advances and future management approaches in the diagnosis of primary aldosteronism.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34798068     DOI: 10.1016/S2213-8587(21)00210-2

Source DB:  PubMed          Journal:  Lancet Diabetes Endocrinol        ISSN: 2213-8587            Impact factor:   32.069


  10 in total

1.  Adrenal venous sampling in primary aldosteronism: Experience of a Spanish multicentric study (Results from the SPAIN-ALDO Register).

Authors:  Marta Araujo-Castro; Miguel Paja Fano; Marga González Boillos; Begoña Pla Peris; Eider Pascual-Corrales; Ana María García Cano; Paola Parra Ramírez; Patricia Martín Rojas-Marcos; Jorge Gabriel Ruiz-Sanchez; Almudena Vicente Delgado; Emilia Gómez Hoyos; Rui Ferreira; Iñigo García Sanz; Mònica Recasens Sala; Rebeca Barahona San Millan; María José Picón César; Patricia Díaz Guardiola; Juan Jesús García González; Carolina M Perdomo; Laura Manjón Miguélez; Rogelio García Centeno; Juan Carlos Percovich; Ángel Rebollo Román; Paola Gracia Gimeno; Cristina Robles Lázaro; Manuel Morales-Ruiz; Felicia A Hanzu
Journal:  Endocrine       Date:  2022-06-25       Impact factor: 3.925

2.  Unilateral Adrenalectomy for Primary Aldosteronism Due to Bilateral Adrenal Disease Can Result in Resolution of Hypokalemia and Amelioration of Hypertension.

Authors:  Thomas Szabo Yamashita; Omair A Shariq; Trenton R Foster; Melanie L Lyden; Benzon M Dy; William F Young; Irina Bancos; Travis J McKenzie
Journal:  World J Surg       Date:  2022-10-07       Impact factor: 3.282

3.  Predictive Factors of Functioning Adrenal Incidentaloma: A 15-Year Retrospective Study.

Authors:  Natwara Muangnoo; Worapaka Manosroi; Napitch Leelathanapipat; Tanaporn Meejun; Pattanan Chowchaiyaporn; Pasinee Teetipsatit
Journal:  Medicina (Kaunas)       Date:  2022-04-27       Impact factor: 2.948

4.  Successful Adrenal Vein Sampling Using Dexamethasone Premedication in Patients With Iodine Contrast Media Allergy.

Authors:  Nada Younes; Eric Therasse; Isabelle Bourdeau; André Lacroix
Journal:  J Endocr Soc       Date:  2022-06-16

5.  [Adrenal diseases].

Authors:  Martin Reincke
Journal:  Internist (Berl)       Date:  2022-01-14       Impact factor: 0.743

Review 6.  Primary aldosteronism: Pathophysiological mechanisms of cell death and proliferation.

Authors:  Martina Tetti; Siyuan Gong; Franco Veglio; Martin Reincke; Tracy Ann Williams
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-08       Impact factor: 6.055

7.  Online prediction model for primary aldosteronism in patients with hypertension in Chinese population: A two-center retrospective study.

Authors:  Wenbin Lin; Wenjia Gan; Pinning Feng; Liangying Zhong; Zhenrong Yao; Peisong Chen; Wanbing He; Nan Yu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-02       Impact factor: 6.055

Review 8.  Stroke Risks in Primary Aldosteronism with Different Treatments: A Systematic Review and Meta-Analysis.

Authors:  Ningjing Qian; Jingmiao Xu; Yaping Wang
Journal:  J Cardiovasc Dev Dis       Date:  2022-09-08

Review 9.  Primary aldosteronism and obstructive sleep apnea: What do we know thus far?

Authors:  Huai Heng Loh; Norlela Sukor
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-29       Impact factor: 6.055

10.  Assessing Outcomes After Adrenalectomy for Primary Aldosteronism - Early is Accurate: Retrospective Cohort Study.

Authors:  Diederik P D Suurd; Wessel M C M Vorselaars; Dirk-Jan Van Beek; Inne H M Borel Rinkes; Wilko Spiering; Gerlof D Valk; Menno R Vriens
Journal:  Ann Surg       Date:  2022-07-27       Impact factor: 13.787

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.